Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    BMJ. 2009 May 29;338:b1846. doi: 10.1136/bmj.b1846.

    Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial.

    Source

    Norwegian Colorectal Cancer Prevention (NORCCAP) Centre, Cancer Registry of Norway, Montebello, NO-0310 Oslo, Norway. hofg@online.no

    Abstract

    OBJECTIVE:

    To determine the risk of colorectal cancer after screening with flexible sigmoidoscopy.

    DESIGN:

    Randomised controlled trial.

    SETTING:

    Population based screening in two areas in Norway-city of Oslo and Telemark county (urban and mixed urban and rural populations).

    PARTICIPANTS:

    55 736 men and women aged 55-64 years.

    INTERVENTION:

    Once only flexible sigmoidoscopy screening with or without a single round of faecal occult blood testing (n=13 823) compared with no screening (n=41 913).

    MAIN OUTCOME MEASURES:

    Planned end points were cumulative incidence and mortality of colorectal cancer after 5, 10, and 15 years. This first report from the study presents cumulative incidence after 7 years of follow-up and hazard ratio for mortality after 6 years.

    RESULTS:

    No difference was found in the 7 year cumulative incidence of colorectal cancer between the screening and control groups (134.5 v 131.9 cases per 100 000 person years). In intention to screen analysis, a trend towards reduced colorectal cancer mortality was found (hazard ratio 0.73, 95% confidence interval 0.47 to 1.13, P=0.16). For attenders compared with controls, a statistically significant reduction in mortality was apparent for both total colorectal cancer (hazard ratio 0.41, 0.21 to 0.82, P=0.011) and rectosigmoidal cancer (0.24, 0.08 to 0.76, P=0.016).

    CONCLUSIONS:

    A reduction in incidence of colorectal cancer with flexible sigmoidoscopy screening could not be shown after 7 years' follow-up. Mortality from colorectal cancer was not significantly reduced in the screening group but seemed to be lower for attenders, with a reduction of 59% for any location of colorectal cancer and 76% for rectosigmoidal cancer in per protocol analysis, an analysis prone to selection bias.

    TRIAL REGISTRATION:

    Clinical trials NCT00119912.

    Comment in

    PMID:
    19483252
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC2688666
    Free PMC Article

    Images from this publication.See all images (3)Free text

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk